MECOM and acute myeloid leukemia: The mapping of IKZF1 DNA binding sites in G2DHE impacting EVI1 promoter activity and chromatin co-occupancy with RUNX1 and CEBPA as found in ChIP-SICAP experiments implicate an interaction of IKZF1 with EVI1/GATA2 pathways, which was previously indicated by a study investigating the mutational landscape of EVI1-rearranged AML [31].